Elanco (NYSE: ELAN) director R. David Hoover reports 10,314-share board equity award

Rhea-AI Filing Summary

Elanco Animal Health Inc. director R. David Hoover reported an equity grant tied to his board service. On 11/28/2025, he received 10,314 shares of common stock as an annual equity award in the form of deferred stock units at a stated price of $0, reflecting a non-cash grant for a non-employee director. After this grant, he beneficially owns 106,773 shares of Elanco common stock directly and an additional 210,000 shares through a Revocable Trust and 15,920 shares through the Suzanne A. Hoover Revocable Trust. The filing is made as a Form 4 by a single reporting person in his capacity as a director.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOOVER R DAVID

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/28/2025		A		10,314	A	$0(1)	106,773	D
Common Stock								210,000	I	Revocable Trust
Common Stock								15,920	I	Suzanne A. Hoover Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

	/s/ Amy C. Seidel, as Attorney-in-Fact for R. David Hoover	12/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Elanco Animal Health (ELAN) report for R. David Hoover?

Elanco Animal Health reported that director R. David Hoover received an annual equity grant of 10,314 shares of common stock on 11/28/2025 in the form of deferred stock units.

What is the nature of the 10,314-share grant reported by Elanco (ELAN)?

The 10,314 shares represent deferred stock units granted as an annual equity award to a non-employee member of Elanco’s Board of Directors, reported at a price of $0 as a non-cash grant.

How many Elanco (ELAN) shares does R. David Hoover own after this transaction?

Following the grant, R. David Hoover beneficially owns 106,773 shares of Elanco common stock directly, plus 210,000 shares through a Revocable Trust and 15,920 shares through the Suzanne A. Hoover Revocable Trust.

What is R. David Hoover’s relationship to Elanco Animal Health (ELAN)?

R. David Hoover is reported as a director of Elanco Animal Health Inc. and is a non-employee member of the company’s Board of Directors.

What SEC form was used to report this Elanco (ELAN) insider transaction?

The transaction was reported on Form 4, which discloses changes in the beneficial ownership of equity securities by company insiders such as directors and officers.

Was the Elanco (ELAN) equity grant to R. David Hoover part of a regular compensation program?

Yes. The filing explains that the grant of deferred stock units is an annual equity award to each non-employee member of Elanco’s Board of Directors.